ArticleBMC cancer2026
CS2164 combined with radiation suppressed tumor growth via γ-H2AX persistence and ROS accumulation.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCS2164 is an oral multi-target inhibitor that targets angiogenesis-related kinases, mitosis-related kinases, and chronic inflammation-related kinases. However, the added clinical benefit of CS2164 combined with radiation remains unknown.
methodsThe anti-tumor effect of CS2164 combined with radiation were evaluated by CCK-8, colony formation assays and xenograft radiation models (n = 5/per group), based on the hepatocellular carcinoma cells (Huh-7) and cervical cancer cells (HeLa). Meanwhile, the γ-H2AX expression, cell cycle distribution, reactive oxygen species (ROS) assay and transcriptome sequencing analysis of xenografts were performed selected to clarify the mechanism.
resultsCS2164 combined with radiation effectively decreased growth of the above tumor cells, compared with CS2164 or radiation alone. The sensitivity enhancement ratio (SER, SER=D0(control group) / D0(treated group)) of CS2164 was 1.406 in HeLa cells and 1.123 in Huh-7 cells, respectively. Similar antitumor effects were observed in xenograft radiation models. The results of GO, KEGG pathway and PPI analysis screened out a series of genes that related to DNA damage repair process, oxidation-reduction reaction, and multiple cell death types. Therefore, γ-H2AX expression, cell cycle distribution and ROS assay were detected. There was no significant difference in the number of γ-H2AX foci between control and CS2164-treated cells. While the numbers of γ-H2AX foci increased in the CS2164-treated (3µM) cells after radiation (4 Gy) at 3 and 6 h, compared to cells treated with radiation alone (p < 0.05). Meanwhile, more cells were observed to be blocked in G2/M phase after treatment of CS2164 combined with radiation, compared with CS2164 or radiation alone. Moreover, the ROS level increased after treatment of CS2164 combined with radiation, which could be partially rescued by oxidation scavenger, NAC.
conclusionOur study demonstrates anti-tumor efficacy of CS2164 combined with radiation in treatment of malignant tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.